Walethmade%2525252525252525252525252525252525252525252525252525252525252525252525252520bromide

# Walethmade bromide (Glycopyrrolate) ## Overview Walethmade bromide is the generic name for **glycopyrrolate**, a synthetic quaternary ammonium anticholinergic agent. It does not cross the blood-brain barrier significantly, resulting in fewer central nervous system side effects compared to atropine or scopolamine. ## Primary Indications * **Preoperative:** Reduction of salivary, tracheobronchial, and pharyngeal secretions. * **Intraoperative:** Reversal of muscarinic effects of cholinergic agents (e.g., neostigmine) or attenuation of bradycardia. * **Peptic Ulcer:** Adjunctive treatment (historical use). * **Chronic Sialorrhea:** Management of severe drooling associated with neurologic conditions (e.g., cerebral palsy). ## Adult Dosing * **Preanesthetic/Antisialogogue:** 0.1 mg to 0.2 mg IM/IV administered 30–60 minutes prior to anesthesia. * **Reversal of Neuromuscular Blockade:** 0.2 mg IV for every 1 mg of neostigmine administered. * **Chronic Sialorrhea (Oral solution):** Initiate at 1.5 mg orally 3 times daily; titrate based on response and tolerability. ## Pediatric Dosing * **Preanesthetic/Antisialogogue:** 0.004–0.01 mg/kg IM/IV (max 0.2 mg per dose). * **Chronic Sialorrhea (Oral solution/Tablet):** Dosing is weight-based. Recommended starting dose is 0.02 mg/kg orally 3 times daily, titrated every 5–7 days to a maximum of 0.1 mg/kg or 1.5–3 mg per dose (refer to specific product labeling for weight-stratified increments). ## Dose Adjustments * **Renal Impairment:** Use with caution. Glycopyrrolate is primarily renally cleared. Dose reduction or increased dosing intervals are required in patients with ESRD or significant impairment to avoid accumulation. ## Contraindications * Hypersensitivity to the drug. * Narrow-angle glaucoma. * Obstructive uropathy (e.g., prostatic hypertrophy). * Myasthenia gravis (unless used to treat muscarinic side effects of anticholinesterases). * Obstructive GI disease (e.g., pyloric stenosis, paralytic ileus). * Severe ulcerative colitis or toxic megacolon. * Tachycardia secondary to cardiac insufficiency or thyrotoxicosis. ## Adverse Effects * **Common:** Xerostomia (dry mouth), constipation, urinary retention, blurred vision (mydriasis/cycloplegia), and flushing. * **Serious:** Tachycardia, palpitations, heat prostration (decreased sweating at high ambient temperatures), and paradoxical excitation. ## Key Drug Interactions * **Anticholinergics:** Additive toxicity with antihistamines, tricyclic antidepressants, or other antispasmodics. * **Potassium Chloride:** Solid oral dosage forms of KCl may show increased risk of GI mucosal lesions when taken with anticholinergics due to prolonged transit time. * **Digoxin:** Anticholinergics may increase serum levels of digoxin by slowing GI motility and increasing bioavailability. ## Monitoring * Monitor heart rate and rhythm, particularly following IV administration for reversal of bradycardia. * Assess for urinary retention and constipation, especially in pediatric patients or the elderly. * Monitor for signs of heat-related illness during hot weather or high physical activity. ## Clinical Pearls * Glycopyrrolate is a **poor** bronchodilator compared to ipratropium/tiotropium and is not used for asthma/COPD management. * Because it is a quaternary ammonium compound, it has minimal central effects (e.g., confusion, delirium) compared to atropine. * Dosing for chronic sialorrhea requires careful titration; discontinue if the patient experiences extreme constipation or urinary retention. *** **Educational Disclaimer:** This information is for educational purposes only. Always verify drug doses, contraindications, and drug interactions against the most current prescribing information (e.g., package insert, Lexicomp, or UpToDate) and adhere to local institutional protocols before prescribing or administering medication.